Liquid Chromatography development for determination of ebastine in pharma
A new method has been developed for determining ebastine in pharma preparations

HPLC, UHPLC

Liquid Chromatography development for determination of ebastine in pharma

12 May, 2011

Published over 15 years ago. See the latest and most current information on HPLC, UHPLC.

Scientists have developed a new method for determining ebastine in its pharmaceutical preparations, according to 7th Space Interactive.

The news source reported that this model depends on the complexation ability of the studied drug with Zn2+ ions.
Reversed phase chromatography was carried out using an ODS c18 stainless steel column with UV-detection at 260nm.

Furthermore, a mobile phase containing 0.025 per cent w/v Zn2+ in a mixture of (acetonitril/methanol) and Britton Robinson buffer, which was adjusted to a pH of 4.2, was used to determine the ebastine at a flow rate of one ml/min.

It was also reported that content uniformity testing of the method was also conducted, while the make-up of the complex and its stability constant was looked into.

Recently, liquid chromatography was used to analyse endometrial hyperplasia and carcinoma, with findings published in the Journal of Hematology and Oncology, highlighting that these gynaecological malignancies are the most common.

Latest News

Explore Our Other Sites

Labmate Online
Fungal and bacterial triggers may be drivers in steroid-resistant asthma
Explore more Arrow
Envirotech Online
New oxygen sensor range targets OEM gas detection applications
Explore more Arrow
Pollution Solutions Online
Skid-mounted systems target oxygen and moisture removal for renewable natural gas
Explore more Arrow
Petro Online
Automated freezing-point testing arrives for jet fuel: what ASTM D8615 changes for lab workflows
Explore more Arrow